Hollander David
CMO & Global Therapeutics Lead at Revance Therapeutics, Inc.
- Sold, on record
- $16k
- Dollars the filings state
- Form 4 sales
- 1
- Latest Nov 18, 2024
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Revance Therapeutics, Inc.CMO & Global Therapeutics Lead
Sales by reason
0
Routine
0
Plan not stated
1
No plan
0
Unusual
Form 4 sales per month, every sale on record.
Timeline
- Nov 18, 2024No plan
Sold 3.6% of their holdings
$16k3,908 shares at $4.17
1 of 1
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Sep 3, 2026 | MANE | Chief R&D Officer | AwardedStock Option (Right to Buy) | 19,300 | 19,300 | SEC | ||
| Sep 1, 2026 | Sep 3, 2026 | MANE | Chief R&D Officer | Awarded | 9,650 | 9,650 | SEC | ||
| Jun 10, 2026 | Jun 12, 2026 | KPRX | Director | AwardedStock Option (right to buy) | 25,000 | 25,000 | SEC | ||
| Apr 1, 2025 | Apr 2, 2025 | KPRX | Director | AwardedStock Option (right to buy) | 20,000 | 20,000 | SEC | ||
| Feb 6, 2025 | Feb 6, 2025 | Revance Therapeutics, Inc. | CMO & Global Therapeutics Lead | Returned to the company | 95,212 | 0 | SEC | ||
| Feb 4, 2025 | Feb 6, 2025 | Revance Therapeutics, Inc. | CMO & Global Therapeutics Lead | Tendered | 9,733 | $3.65 | $36k | 95,212 | SEC |
| Nov 18, 2024 | Nov 19, 2024 | Revance Therapeutics, Inc. | CMO & Global Therapeutics Lead | Sold | 3,908 | $4.17 | $16k | 104,945 | SEC |
| Jul 1, 2024 | Jul 3, 2024 | KPRX | Director | AwardedStock Option (right to buy) | 1,778 | 1,778 | SEC | ||
| Mar 3, 2023 | Mar 7, 2023 | KPRX | Director | AwardedStock Option (right to buy) | 8,000 | 8,000 | SEC | ||
| Feb 4, 2022 | Feb 8, 2022 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | Withheld for tax | 927 | $7.05 | $7k | 30,749 | SEC |
| Feb 1, 2022 | Feb 3, 2022 | KPRX | Director | AwardedStock Option (right to buy) | 9,000 | 5,000 | SEC | ||
| Nov 11, 2021 | Nov 15, 2021 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | Withheld for tax | 2,162 | $12.06 | $26k | 31,676 | SEC |
| Feb 4, 2021 | Feb 8, 2021 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | AwardedStock option (right to buy) | 50,000 | 50,000 | SEC | ||
| Feb 4, 2021 | Feb 8, 2021 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | Awarded | 11,000 | 33,838 | SEC | ||
| Nov 11, 2020 | Nov 12, 2020 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | Withheld for tax | 2,162 | $13.05 | $28k | 22,838 | SEC |
| Nov 11, 2019 | Nov 13, 2019 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | AwardedStock Option (right to buy) | 110,000 | 110,000 | SEC | ||
| Nov 11, 2019 | Nov 13, 2019 | AERIE PHARMACEUTICALS INC | Chief R&D Officer | Awarded | 25,000 | 25,000 | SEC |
Sales and notices (1)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | Nov 19, 2024 | Revance Therapeutics, Inc. | CMO & Global Therapeutics Lead | Form 4 sale | 3,908 | $16k | 3.6% | No plan | SEC |